Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479348 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Study for FdCyd and THU Cancer Treatment
A Early Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01479348: Clinical Trial Early Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01479348 is a Early Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01479348, a Early Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Background: \- The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging studies to see how the drug reacts with the cancer. This study is not a treatment study. It is open only to people who are already on the FdCyd and THU cancer treatment study. Objectives: \- To study how FdCyd affects advanced cancer cells. Eligibility: \- Participants in National Cancer Institute study 09-C-0214. Design: * Participants will have two imaging studies, one before starting FdCyd and THU treatment and one after starting treatment. * Participants will have the modified FdCyd, known as F-18 FdCyd, with a dose of THU. The doses will be followed by two imaging study scans and frequent blood samples. * This procedure will be repeated at a later date, during the FdCyd and THU treatment period. * Treatment will not be provided as part of this study. This is an imaging study protocol only....
Interventions
- DRUG [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
- DRUG Tetrahydrouridine intravenous (IV)
- DRUG Tetrahydrouridine (oral)
- DIAGNOSTIC_TEST Positron emission tomography (PET)/Computed tomography (CT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-11-01 |
| Est. Completion | 2019-01-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479348
The ClinicalTrials.gov registry entry for NCT01479348 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which [F-18]-5-FLUORO-2'-DEOXYCYTIDINE is the first listed.
NCT01479348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479348 about?
NCT01479348 is a clinical study titled "Imaging Study for FdCyd and THU Cancer Treatment". Background: \- The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging studies to see how the ...
What is the current status of trial NCT01479348?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2011-11-01. Estimated completion is 2019-01-11.
What interventions are being tested in trial NCT01479348?
The interventions under investigation include: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE (DRUG), Tetrahydrouridine intravenous (IV) (DRUG), Tetrahydrouridine (oral) (DRUG), Positron emission tomography (PET)/Computed tomography (CT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01479348?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.